MAXXIM MEDICAL, BIOMET RAISE STAKES FOR KIRSCHNER
This article was originally published in The Gray Sheet
Executive Summary
MAXXIM MEDICAL, BIOMET RAISE STAKES FOR KIRSCHNER as Biomet announces July 15 a revised merger offer. The new Biomet offer proposes $10.75 per Kirschner share or an equivalent value of Biomet stock. This bid marks the third offer made by Biomet, and it comes in response to two proposals which were delivered to Kirschner by Maxxim Medical during the week of July 11.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.